$FBRX who remembers the atopic dermatitis days from 5 years ago? - what a pivot
361
$ABVX this ecco abstract shows the prostate cancer stage 1 from induction trial.
ABTECT is a rerandomized responder design, so a patient flows from induction into maintenance. A stage I prostate detected during induction belongs to a pt who then continued into maintenance on 50
correct me if im wrong but this has gotta be the same prostate patient ... ? same one from induction into maintenance on 50mg $abvx
$ABVX for anyone confused / wondering what to think
50mg at w96 and w144 = NO NEW safety signals, no breast/prostate/NMSCs...
obe won't just cause cancer within 60 days
we'll be ok
If obe were driving oncogenesis you would expect 25mg to sit somewhere between placebo/50 mg...second, organ scatter - real carcinogens concentrate. The JAK class black box was established in a 4,362-patient dedicated trial (lung NHL), not from five lineages appearing once
$ABVX
5
21
3,240
$ABVX The colonic dysplasia is especially telling too - dysplasia is precancerous, UC pts undergo surveillance c-scopy, and protocol required baseline endoscopy. A dysplastic focus found 60 days into dosing was almost certainly present already. same applies to prostate &breast
9
769
$ABVX Prostate cancers double roughly every 2–4 years, and prostate cancer is extraordinarily common as occult/latent disease in this demographic ... Bell et al. found histologic prostate cancer in 21% of men across all ages
6
542
$ABVX if there was clustering , I'd sell. but there isn't. instead you have high incidence cancers. breast at a 200-day doubling time needs 20 years to reach 1–2 cm; even an aggressive 100-day doubling time needs 10 years & a remarkably fast 20day doubling tumor still needs 2yrs
1
8
683
$ABVX also if PI caught cancer within 60 day latency -- highly likely they were just present but undiagnosed at enrollment
Looking beyond JAKs, S1P modulators etrasimod (Velsipity) and ozanimod (Zeposia) carry no boxed warning; cutaneous malignancy is mere Warnings/Precaution
10
829
(25/25) $ABVX Takeaways
3. Do NOT see this as an academic exercise. It's a positioning campaign + laying the railway tracks for commercialization. Every discount pathway is closed now =higher buyout price commanded. FFS might BTC my 220 calls now
/fin and happy lunar new year!
2
23
3,374
(24/n) $ABVX TAKEAWAYS
2. reframing obe as more than an anti-inflammatory.. the fibrosis abstract is HUGE - If miR-124 modulation shows anti-fibrotic signal in IBD models, they’re hinting at disease mod. In Crohn’s especially, fibrosis = unmet need + surgical burden = higherSP














